Commentary
PTK2/FAK: a new predictive biomarker for response to radiotherapy in head and neck squamous cell carcinoma
Abstract
With over 600,000 new cases per year worldwide, head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy in developed countries (1).
